论文部分内容阅读
目的:对尿激酶天普洛欣静脉溶栓治疗急性心肌梗塞的临床疗效进行探讨。方法:抽取2014年1月至2015年10月期间,于我院接受治疗的84例急性心肌梗塞患者作为本次研究对象,并依据使用剂量的不同将其分为对照组与观察组,对照组患者予以剂量为150万单位的治疗,观察组患者予以剂量为200万单位的治疗,对两组患者治疗所取得的疗效进行观察、对比。结果:两组患者血管再通率、病死率以及副作用发生情况之间的数据对比,经检验并无统计学差异存在(P>0.05)。结论:尿激酶天普洛欣静脉溶栓治疗急性心肌梗塞疗效确切,安全可靠,且价格低廉,在临床上可进行积极推广、应用。
Objective: To investigate the clinical effect of intravenous thrombolysis of urokinase on acute myocardial infarction. Methods: A total of 84 acute myocardial infarction patients treated in our hospital from January 2014 to October 2015 were selected as the study subjects, and divided into control group, observation group and control group according to different dosage Patients were treated with a dose of 1.5 million units, and patients in the observation group were treated with a dose of 2 million units. The therapeutic effects of the two groups of patients were observed and compared. Results: There was no significant difference between the two groups in the rate of recanalization, mortality and the incidence of side effects (P> 0.05). Conclusion: Thrombolytic therapy of Urokinase-th e prophylaxis for acute myocardial infarction is effective, safe and reliable, and its price is low. It can be actively promoted and applied clinically.